ACE and peripheral arterial disease: In this cohort study, we examined the prescription rate of OMT, defined as the use of at least one antiplatelet agent, statin and ACE inhibitor or AT-2 antagonist and its impact on all-cause mortality, amputation-free survival and freedom from CD TLR in patients with PAD undergoing infrapopliteal intervention.